DFAME is a red fluorophore (Ex=508 nm, Em=641 nm). Beetroot and Corn are dimeric fluorogenic RNA aptamers that can bind to DFAME to form Beetroot-DFAME (Kd=460nM) and Corn-DFAME (Kd= 3600nM). Beetroot-DFAME (Kd=460nM) and Corn-DFAME can be used to form RNA assemblies in living cells. Creating RNA assemblies can be used for the study of RNA Nanostructures. DNA/RNA Nanostructures would be useful in cell and gene therapy (CGT) research.

L-369 (Lipid 369,L369) is novel class of ionizable lipid for siRNA delivery with improved in vivo elimination profile with excellent translation across species,including NHP, wide safety margin.

Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a glucagon-like peptide-1 (GLP-1R)/glucagon receptor GCGR co-agonist. Mazdutide has safety and tolerability, and it can be used for research in obesity and type 2 diabetes (T2D).

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.

Iso-A11B5C1 is an ionizable lipid. The iso-A11B5C1 LNP demonstrates a high level of muscle-specific mRNA delivery efficiency. exhibiting transfection efficiency comparable to the commercially available lipid SM-102, while considerably reducing inadvertent mRNA expression in main organs such as the liver and spleen.Additionally, study results show that intramuscular administration of mRNA formulated with iso-A11B5C1 LNP caused potent cellular immune responses, even with limited expression observed in lymph nodes.

RLY-2608 is an oral allosteric pan-mutant isoform-selective PI3K伪 inhibitor that was discovered using MD modeling and cryo-EM to identify allosteric networks and opportunities for small molecules, followed by DEL screening.

LY3522348 is a highly selective, oral dual inhibitor of human ketohexokinase isoforms C and A (hKHK-C, hKHK-A). LY3522348 displayed a robust pharmacodynamic response in a mouse model of fructose metabolism and was advanced into clinical trials.

Pelcitoclax, also known as APG 1252 and BM1251, is a potent and selective Bcl-2/Bcl-XL inhibitor. APG-1252 A Bcl-2 homology (BH)-3 mimetic and selective inhibitor of the anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2) and Bcl-XL, with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2/Bcl-XL inhibitor APG-1252 specifically binds to and inhibits the activity of the pro-survival proteins Bcl-2 and Bcl-XL. This restores apoptotic processes and inhibits cell proliferation in Bcl-2/Bcl-XL-dependent tumor cells.

SF001 is an experimental antifungal drug based on amphotericin B (AmB) that is engineered to be less toxic to the kidneys

INX-315 is a novel and potent CDK2 inhibitor with IC50 of 2.3 nM and shows high selectivity over other CDK family members (374 nM against CDK1/cyclin and 950 nM against CDK9/cyclin,respectively). INX-315 promotes retinoblastoma protein hypo-phosphorylation and therapy-induced senescence (TIS) in CCNE1-amplified tumors, overcomes breast cancer resistance to CDK4/6i and delays the onset of CDK4/6i resistance in breast cancer.

TRIM-473 is a novel ligand for the PRY-SPRY domain of the E3 RING ligase TRIM58 with EC50 of 5.3 μM.

Compoud 18 (AEP inhibitor) is first orthosteric, selective, orally bioavailable, and brain penetrant inhibitor with IC50 of 7.8 nM against asparagine endopeptidase (AEP) with an irreversible binding mode.

ACBI3 is a selective, potent and in vivo active pan-KRAS PROTAC degrader, potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles (DC50=3.9 nM in GP2d cells).

 ABBV-467 is a selective MCL-1 inhibitor. In vivo, intermittent dosing of ABBV-467 as monotherapy or in combination with venetoclax inhibits the growth of xenografts from human hematologic cancers.

BMS-502 is a dual DGKα and ζ inhibitor. BMS-502 demonstrated dose-dependent immune stimulation in the mouse OT-1 model, setting the stage for a drug discovery program.

Pociredir is an embryonic ectoderm development (EED) protein inhibitor. Pociredir can be used for the research of inflammatory or hemoglobinopathies, such as sickle cell disease.

TP0472993 is an oral 20-hydroxyeicosatetraenoic acid synthesis inhibitor

CT-3 is an irreversible trypanosomal topo. II inhibitor.

 GNE-7883 is a pan-TEAD inhibitor.

KCL-286 is an oral RARβ agonist.

AEF0117 is a Signaling-specific CB1 inhibitor.

LUNA18 is an 11-mer cyclic peptide inhibitor for the intracellular tough target RAS with Kd (KRAS/G12D) of 0.043 nM and cellular IC50 of 1.4 nM (AsPC-1). LUNA18 orally and dose-dependently exhibits potent anti-cancer activities in a mouse xenograft model. LUNA18 shows 21–47% oral bioavailability in animals such as mouse, rat, monkey, and dog and notably does not require special formulations.